Journal Mobile Options
Table of Contents
Vol. 61, No. 4, 1980
Issue release date: 1980
Section title: Original Paper
Int. Archs Allergy appl. Immun 1980;61:441–448
(DOI:10.1159/000232472)

Allergenicity of Major Component Proteins of Soybean

Shibasaki M. · Suzuki S. · Tajima S. · Nemoto H. · Kuroume T.
Department of Pediatrics, Gunma University School of Medicine, Maebashi, Gunma

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 7/15/1979
Published online: 7/29/2009

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA

Abstract

Allergenic activities of major component proteins of soybean 11S-, 7S- and 2S-globulins were examined by the radioallergosorbent test (RAST) and by RAST inhibition experiments with the sera from soybean-sensitive patients. The reactivity with specific IgE antibody was found in all fractions. There was considerable cross-reactivity among three fractions, and 2S-globulin had the highest allergen potency to inhibit the RAST against 11S-, 7S- and 2S-globulin. When the fractions were heat-treated at 80, 100 and 120 °C for 30 min, the RAST reactivity of 2S-globulin heated at 80 °C for 30 min was slightly enhanced, while that of others was reduced to 39–75% of that of the native globulin. IgE antibody could be produced in BALB/c mice only with one of the three fractions, i. e. 2S-globulin, and the produced IgE antibody lacked reactivity with 11S- and 7S-globulin.


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 7/15/1979
Published online: 7/29/2009

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.